Stonepine Capital Management LLC Cuts Stock Holdings in Exagen Inc. (NASDAQ:XGN)

Stonepine Capital Management LLC lessened its position in shares of Exagen Inc. (NASDAQ:XGN - Free Report) by 53.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 251,049 shares of the company's stock after selling 283,349 shares during the quarter. Stonepine Capital Management LLC owned about 1.42% of Exagen worth $1,029,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Toronto Dominion Bank purchased a new position in Exagen in the fourth quarter worth $3,655,000. Driehaus Capital Management LLC acquired a new stake in shares of Exagen in the 4th quarter worth $1,716,000. Marshall Wace LLP acquired a new stake in shares of Exagen in the 4th quarter worth $66,000. Kennedy Capital Management LLC grew its stake in Exagen by 8.8% during the 4th quarter. Kennedy Capital Management LLC now owns 184,473 shares of the company's stock worth $756,000 after buying an additional 14,920 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in Exagen during the 4th quarter valued at about $46,000. Institutional investors own 75.25% of the company's stock.

Exagen Stock Performance

XGN traded up $0.83 during trading on Friday, reaching $6.86. 348,163 shares of the company's stock were exchanged, compared to its average volume of 113,611. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. Exagen Inc. has a 1 year low of $1.71 and a 1 year high of $7.20. The company's fifty day simple moving average is $5.01 and its 200-day simple moving average is $4.31. The stock has a market capitalization of $146.14 million, a P/E ratio of -7.30 and a beta of 1.50.

Exagen (NASDAQ:XGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The company had revenue of $15.50 million during the quarter, compared to the consensus estimate of $14.55 million. During the same period in the previous year, the firm posted ($0.19) earnings per share. As a group, research analysts predict that Exagen Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. William Blair reissued an "outperform" rating on shares of Exagen in a report on Wednesday, March 12th. BTIG Research reaffirmed a "buy" rating on shares of Exagen in a research report on Wednesday, May 7th. Canaccord Genuity Group boosted their target price on shares of Exagen from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Tuesday, May 13th. Cantor Fitzgerald cut their price target on shares of Exagen from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Finally, UBS Group reaffirmed an "overweight" rating on shares of Exagen in a report on Thursday, May 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $7.50.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).